natgillin/translations-raw huggingface dataset:
lesions are not ulcerated or lymphoedematous, and treatment of visceral KS is not required, and lesions are not responding to systemic antiretroviral therapy, and radiotherapy or chemotherapy are not appropriate
lezije niso zagnojene in se niso razvili limfedemi, ter zdravljenje visceralnega KS ni potrebno, ter če se lezije ne odzovejo na sistemsko antiretrovirusno terapijo, ter če radioterapija ali kemoterapija nista primerni
Panretin therapy should only be initiated and maintained by specialist physicians experienced in the treatment of patients with KS.
Terapijo s Panretinom naj predpiše in nadzoruje le zdravnik specialist, ki ima izkušnje z zdravljenjem KS bolnikov.
Patients should apply Panretin gel to cutaneous KS lesions using sufficient gel so as to cover each lesion with a generous coating.
Bolniki nanesejo Panretin gel na kožne KS lezije, in sicer tako, da z zadostno količino gela pokrijejo vsako lezijo z ustrezno plastjo.
Frequency of application Patients should initially apply Panretin gel twice a day to cutaneous KS lesions.
Pogostost uporabe Bolniki naj na začetku nanesejo Panretin gel dvakrat dnevno na kožne KS lezije.
There are no data on the efficacy of Panretin gel applied less frequently than twice daily.
Ni podatkov o učinkovitosti Panretin gela, če se ta nanaša manj kot dvakrat dnevno.
Local dermal irritation may be graded according to the five-point scale shown in Table 1.
Lokalno draženje kože se lahko razvrsti po pet- točkovni lestvici, prikazani v razpredelnici 1.
2 Table 1:
2 Razpredelnica 1:
Grading of local dermal irritation
Razvrščanje glede na lokalno draženje kože
GRADE 0 = No Reaction 1 = Mild 2 = Moderate 3 = Severe 4 = Very Severe
STOPNJA 0 = Brez reakcije 1 = Blago 2 = Zmerno 3 = Hudo 4 = Zelo hudo
DEFINING CLINICAL SIGNS None Definite pink to red coloration Increased redness, possible oedema Very red, with oedema, with or without vesiculation Deep red, swelling and oedema with or without signs of bullae formation and necrosis
OPREDELITEV KLINIČNIH ZNAKOV Brez Razločna rožnata do rdeča barva Povečana pordelost, morebitni edem Zelo rdeče, z edemom, z ali brez mehurjenja Intenzivno rdeče, oteklina in edem z ali brez znakov nastajanja bul in nekroze
Adjustment guidelines for treatment-limiting toxicity
Smernice za prilagoditev odmerjanja pri toksičnosti, ki omejuje zdravljenje
Grade 0, 1 or 2 Grade 3
Stopnja 0, 1 ali 2 Stopnja 3
When dermal irritation improves to Grade 0 or 1, treatment may be restarted at twice daily, increasing every two weeks as tolerated.
Povečanje je možno vsaka dva tedna, odvisno od odziva kože.
Duration of application It is recommended that Panretin gel should be applied to lesions for an initial period of up to 12 weeks.
Trajanje uporabe Priporočamo, da se Panretin gel nanaša na lezije v začetnem obdobju, ki traja do 12 tednov.
Treatment of lesions that have not shown a decrease in area and/ or height by week 12 should be discontinued.
Zdravljenje lezij, ki se niso zmanjšale po površini oz. višini do 12. tedna, je treba prekiniti.
For those lesions that have shown a decrease in height and/ or area by week 12, applications may be continued providing that there is continued improvement or at least maintenance of the response and that the product continues to be tolerated.
Uporaba zdravila se lahko podaljša za lezije, pri katerih se je pokazalo zmanjšanje po višini oz. površini do 12. tedna pod pogojem, da se pokaže nadaljnje izboljšanje oz. vsaj ohranitev odziva ter da bolnik zdravilo še naprej prenaša.
Patients should wash their hands before and after applications; it is not necessary to wear gloves.
Uporaba rokavic ni potrebna.
Care must be taken to avoid application of the gel to normal skin surrounding the lesions.
Posebna pozornost je potrebna pri nanosu gela, saj se le- ta ne sme nanesti na zdravo kožo ob leziji.
AIDS-related Kaposi’ s sarcoma is infrequent in women.
Kaposi- jev sarkom kot posledica AIDS- a je redek pojav pri ženskah.
Children and adolescents
Otroci in mladina
Panretin is not recommended for children below 18 years of age due to a lack of data on safety and efficacy.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba Panretin pri otrocih pod 18 let ni priporočljiva.
AIDS-related Kaposi’ s sarcoma is infrequent in this population.
Kaposi- jev sarkom kot posledica AIDS- a je redek pojav pri tej skupini bolnikov.
3 Renal or hepatic impairment
3 Ledvična ali jetrna obolenja
There are no data regarding the use of Panretin gel in patients with renal insufficiency or liver disease.
Ni podatkov glede uporabe Panretin gela pri bolnikih z ledvično insuficienco ali jetrno boleznijo.
Pharmacokinetic studies indicate that the range and frequency of detection of quantifiable 9-cis- retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis-retinoic acid in untreated individuals (see section 5.2).
S farmakokinetičnimi raziskavami so ugotovili, da sta obseg in pogostost odkritja merljive koncentracije 9- cis- retinoidne kisline v plazmi pri KS bolnikih po nanosu zdravila primerljivi z obsegom in pogostostjo merljive koncentracije 9- cis- retinoidne kisline v obtoku v plazmi, ki se naravno pojavi pri nezdravljenih posameznikih (glejte poglavje 5. 2).
On a theoretical basis, no dosage adjustment is necessary in patients with renal insufficiency or liver disease, but these patients should be closely monitored and treatment frequency reduced, or withdrawn, if they experience adverse effects.
V primeru pojava neželenih učinkov je treba pogostost nanosa zmanjšati ali zdravljenje v celoti prekiniti.
Panretin gel is contraindicated in
Panretin gel je kontraindiciran
• Patients with hypersensitivity to retinoids in general, to alitretinoin or to any of the excipients. • Pregnancy and during breast-feeding (see section 4.6). • The treatment of KS lesions in close proximity to other skin disorders.
• pri bolnikih s splošno preobčutljivostjo za retinoide, za alitretinoin ali za pomožne snovi zdravila. • v času nosečnosti ter v času dojenja (glejte poglavje 4. 6). • pri zdravljenju KS lezij, ki se pojavijo v neposredni bližini drugih bolezni kože.
There were no reports of photosensitivity associated with the use of Panretin gel in the clinical studies.
Celotno skupino etinoidov povezujejo z občutljivostjo za svetlobo.
However, patients must be cautioned to minimise exposure of treated areas to sunlight or other ultraviolet (UV) light (such as tanning lamps) (see section 5.3).
(Glejte poglavje 5. 3)
Women of child-bearing potential must use a reliable form of contraception during treatment with Panretin gel (see section 4.6) and until one month after cessation of treatment.
Plodne ženske morajo v času zdravljenja kot tudi en mesec po prenehanju zdravljenja s Panretin gelom (glejte poglavje 4. 6) uporabljati učinkovito kontracepcijsko sredstvo.
Avoid the use of other topical products on treated KS lesions.
Izogibati se je potrebno nanosu oz. uporabi drugih lokalnih izdelkov na zdravljene KS lezije.
Mineral oil may be used between Panretin gel applications in order to help prevent excessive dryness or itching.
Za preprečitev prekomerne izsušenosti kože in srbenja se lahko v obdobjih med aplikacijami Panretin gela nanese mineralno olje.
However, mineral oil should not be applied for at least two hours before or after the application of Panretin gel.
Mineralno olje pa se ne sme nanesti najmanj dve uri pred in po nanosu Panretin gela.
It is not recommended for patients to apply Panretin gel concurrently with products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
Bolnikom ne priporočamo uporabo Panretin gela hkrati z izdelki, ki vsebujejo DEET (N, N- dietil- m - toluamid), kar je običajna sestavina pri sredstvih za zaščito pred insekti (repelenti).
Animal toxicology studies showed increased DEET toxicity when DEET was included as part of the formulation.
V toksikoloških raziskavah na živalih so ugotovili povečano toksičnost DEET, kadar je bil le- ta prisoten med sestavinami izdelka.
The range and frequency of detection of quantifiable plasma 9-cis-retinoic acid concentrations in patients with KS applying the medicinal product to up to 64 lesions were comparable to respective values in untreated patients.
Obseg in pogostost odkritja merljive koncentracije 9- cis- retinoidne kisline v plazmi pri KS bolnikih, ki jim je bilo zdravilo nanešeno na do 64 lezij, sta bila primerljiva z zadevnimi vrednostmi pri bolnikih, ki se niso zdravili.
While no data are available, it is possible that coadministration of medicinal products which induce CYP isozymes may reduce circulating levels of alitretinoin, with a possible negative effect on the efficacy of Panretin gel.
Čeprav ni razpoložljivih podatkov, je možno, da sočasna uporaba zdravil, ki inducirajo CYP izoencime, zmanjša nivoje alitretinoina v plazmi, s posledičnim možnim negativnim vplivom na učinkovitost Panretin gela.
Use during pregnancy Panretin gel is contraindicated (see section 4.3) in pregnancy, as alitretinoin may cause foetal harm when administered systemically to a pregnant woman.
Uporaba med nosečnostjo Panretin gel je kontraindiciran (glejte poglavje 4. 3) med nosečnostjo, saj alitretinoin lahko povzroča poškodbe zarodka, kadar se sistemsko daje nosečnicam.
In rabbits, alitretinoin was shown to be teratogenic at a dose which resulted in plasma concentrations about 60 times the highest observed plasma concentration in male patients with KS following topical application of the gel.
Pri kuncih se je alitretinoin pokazal kot teratogen pri odmerkih, pri katerih je bila koncentracija v plazmi 60- krat višja od najvišje opažene koncentracije v plazmi pri moških bolnikih po lokalni uporabi gela.
However, it is not currently certain to what extent topical treatment with Panretin gel would increase 9-cis-retinoic acid plasma concentrations, in women with KS above naturally occurring levels; therefore, alitretinoin should not be used in pregnant women.
Iz tega razloga pri nosečnicah alitretinoina ne smemo uporabiti.
Women of child-bearing potential must use effective contraception during, and up to one month after cessation of, treatment.
Plodne ženske morajo med zdravljenjem in do enega meseca po njegovem prenehanju uporabljati učinkovito kontracepcijsko sredstvo.
Use during lactation It is not known whether this medicinal product is excreted in human milk.
Uporaba med dojenjem Ni znano, ali se alitretinoin izloča preko materinega mleka.
Based on the plasma concentrations observed in patients, milk concentrations of 9-cis-retinoic acid probably pose a low risk for the infant.
Na osnovi koncentracij izmerjenih v plazmi bolnikov, predstavljajo verjetno koncentracije 9- cis- retinoidne kisline v materinem mleku le nizko tveganje za dojenčka.
However, because of the potential for undesirable effects from Panretin gel in infants being breast-fed, mothers must discontinue breast-feeding prior to using the medicinal product and not initiate breast-feeding while using the medicinal product.
Vendar pa morajo matere zaradi možnosti neželenih učinkov pri dojenih otrocih, ki bi bili posledica uporabe Panretin gela, pred uporabo tega zdravila prenehati z dojenjem oz. ne smejo začeti z dojenjem v času uporabe tega zdravila.
Care should be taken not to bring the neonate into skin contact with areas to which Panretin gel has been recently applied.
Posebna pozornost je potrebna, da novorojenec s svojo kožo ne pride v stik s predeli kože bolnika (- ce), na katere je bil pred kratkim nanesen Panretin gel.
Panretin gel is for cutaneous use and is unlikely to have an effect on one’ s ability to drive or operate machinery.
Panretin gel je namenjenuporabi na koži in nima oz. ima le zanemarljiv vpliv na sposobnost vožnje oz. upravljanja s stroji.
Adverse events associated with the use of Panretin gel in AIDS-related KS occurred almost exclusively at the site of application.
Neželeni učinki, povezani z uporabo Panretin gela pri KS- u, ki je posledica AIDS- a, so se domala vedno pojavili samo na mestu nanosa.
The dermal toxicity typically begins as erythema; with continued application of Panretin gel erythema may increase and oedema may develop.
Dermalna toksičnost se značilno pojavi kot eritem.
Dermal toxicity may become treatment-limiting, with intense erythema, oedema, and vesiculation.
Pri nadaljnji uporabi Panretin gela se lahko eritem poveča in se razvije edem.
When applying Panretin gel, 69.1% of patients experienced adverse drug reactions at the application site.
Dermalna toksičnost lahko postane omejujoča za zdravljenje, spremljana z intenzivnim eritemom, edemom ter nastankom mehurjev.
The following application-site drug-related adverse events were reported during clinical studies in patients with KS.
KS bolniki so med kliničnimi študijami poročali o sledečih neželenih učinkih zdravila na mestu aplikacije.
The frequency of adverse events are classified as very common (≥ 1/ 10), common (≥ 1/ 100, < 1/ 10), uncommon (≥ 1/ 1,000, < 1/ 100), rare (≥ 1/ 10,000, < 1/ 1,000), and very rare (< 1/ 10,000).
Pogostost pojavljanja neželenih učinkov je uvrščena kot zelo pogosta (≥1/ 10), pogosta (≥1/ 100, < 1/ 10), občasna (≥1/ 1, 000, < 1/ 100), redka (≥1/ 10, 000, < 1/ 1, 000) in zelo redka (< 1/ 10, 000).
Adverse events include verbatim terms in parentheses.
Neželeni učinki vsebujejo dobesedne navedbe bolnikov v oklepajih.
Blood and lymphatic system disorders Uncommon:
Bolezni krvi in limfatičnega sistema Nepogosto:
Nervous system disorders Common:
Pogosto:
Paraesthesia (stinging, tingling)
Parestezija (skelenje, srbenje)
5 Skin and subcutaneous tissue disorders Very common:
5 Bolezni kože in podkožja Zelo pogosto:
Skin disorder (cracking, scab, crusting, excoriation, drainage, oozing), Rash (erythema, redness, scaling, irritation, dermatitis), Pruritus (itching, pruritus) Common:
kožne motnje (pokanje kože, kraste, krastavost, odrgnine, izločanje tekočine, izcedki), izpuščaji (eritem, pordelost, luskavica, draženje, vnetje kože), pruritus (srbenje, pruritus)
Skin ulcer, Serous drainage, Exfoliative dermatitis (flaking, peeling, desquamation, exfoliation), Skin discoloration (brown discoloration, surrounding hyperpigmentation, paler), Dry skin
Kožne razjede, izločanje serozne tekočine, eksfoliativni dermatitis (luščenje kože, lupljenje, deskvamacija, odstopanje kože), sprememba barve kože (sprememba barve v rjavo, obrobna hiperpigmentacija, bledica kože), suha koža
Cellulitis, Vesiculobullous rash, Maculopapular rash, Allergic reaction
Celulit, vezikularni izpuščaji, makulopapularni izpuščaji, alergična reakcija
Vascular system disorders Common:
Pogosto:
Haemorrhage (bleeding at or around lesions), Oedema (oedema, swelling, inflammation), Peripheral oedema
hemoragija (krvavenje na ali ob leziji), edem (edem, oteklina, vnetje), periferni edem
Phlebitis, Vascular disorder
Flebitis, vaskularne motnje
General disorders and administration site conditions Very common:
Splošne težave in spremembe na mestu aplikacije Zelo pogosto:
Pain (burning, pain, soreness) Uncommon:
Občasno:
Infection, including bacterial infection
Bolečina (pekoča bolečina, bolečina, občutljivost) Okužba, vključno z bakterijskimi povzročitelji
The safety of Panretin gel has been assessed in clinical studies of more than 469 patients with AIDS- related KS, 439 of whom were treated with an alitretinoin concentration of 0.1%.
Varnost Panretin gela je bila ocenjena v kliničnih raziskavah z več kot 469 bolniki, obolelimi z AIDS - om povezanim KS -, od katerih je bilo 439 zdravljenih z 0, 1% - nim alitretinoinom.
The incidence of drug-related skin disorder, skin ulcer, pain and rash appeared to be greater in patients applying Panretin gel four times daily than in those applying it less frequently.
Pojav motnje kože, kožnih razjed, bolečine in izpuščajev kot posledica uporabe zdravila je bil pogostejši pri bolnikih, ki so uporabili Panretin gel štirikrat dnevno v primerjavi s tistimi, ki so ga nanašali manj pogosto.
The incidence of mild/ moderate rash (all events regardless of causality) was less in patients treated for less than 16 weeks than in those treated for 16 weeks or more (mild, 33% v 63%; moderate, 29% v 43%).
33% napram 63%; zmerno:
The incidence of severe skin rash was independent of the duration of treatment (10% in both cases).
Pojav hudih izpuščajev ni bil povezan s trajanjem zdravljenja (10% v obeh primerih).
Local dermal toxicity associated with Panretin gel therapy generally resolved with treatment adjustment or discontinuation (see Section 4.2 for guidance on making treatment adjustments necessitated by toxicity.)
Lokalna dermalna toksičnost, ki je povezana s terapijo s Panretin gelom, je bila večinoma odpravljena s prilagoditvijo zdravljenja ali s prekinitvijo (glejte poglavje 4. 2 o smernicah za prilagoditev zdravljenja, ki je potrebna zaradi toksičnosti.)
The adverse events seen with Panretin gel are similar to those seen with other topical retinoids.
Neželeni učinki, opaženi pri uporabi Panretin gela, so podobni tistim, opaženim pri drugih lokalnih retinoidih.
It is unlikely that the undesirable systemic side effects associated with oral retinoids will be observed with the use of Panretin gel because the range and frequency of quantifiable 9-cis-retinoic acid plasma levels concentrations after application of the medicinal product were comparable to the range and frequency of quantifiable plasma concentrations of circulating, naturally occurring 9-cis-retinoic acid in untreated individuals.
Malo verjetno je, da se neželeni sistemski stranski učinki, povezani z oralnimi retinoidi, opazijo tudi pri uporabi Panretin gela, ker sta bila obseg in pogostost merljive koncentracije 9- cis - retinoidne kisline v plazmi po aplikaciji zdravila primerljiva z obsegom in pogostostjo merljive koncentracije 9- cis- retinoidne kisline, ki kroži in se naravno pojavlja pri posameznikih, ki se ne zdravijo.
Systemic toxicity following acute overdose with topical application of Panretin gel is unlikely.
Sistemska toksičnost po akutnem prevelikem odmerjanju s Panretin gelom je malo verjetna.
Pharmacotherapeutic group: other antineoplastic agents, ATC code:
Farmakoterapevtska skupina: drugi antineoplastiki, Oznaka ATC:
6 Although the molecular action of alitretinoin is thought to be mediated through interaction with the retinoid receptors, the exact mechanism of action of this medicinal product in the topical treatment of cutaneous lesions of AIDS-related KS is unknown.
6 Čeprav se za molekularno delovanje alitretinoina misli, da je posredovano z njegovim medsebojnim delovanjem z retnoidnimi receptorji, natančni mehanizem delovanja tega zdravila pri lokalnem zdravljenju kožnih lezij, ki nastanejo zaradi z AIDS- om povezanim KS ni znan.
Alitretinoin (9-cis-retinoic acid), a naturally- occurring endogenous hormone related to vitamin A, binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ).
Alitretinoin (9- cis - retinoidna kislina), je naravno prisoten endogeni hormon, soroden z vitaminom A, ki se veže na in aktivira vse znane znotrajcelične podtipe retinoidne receptorje (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ).
The efficacy of Panretin gel in treating KS lesions may be related to the demonstrated ability of alitretinoin to inhibit the in vitro growth of KS cells.
Učinkovitost Panretin gela pri zdravljenju KS lezij se lahko poveže z ugotovljeno sposobnostjo alitretinoina za inhibicijo rasti KS celic in vitro.
Panretin gel can be expected to have local therapeutic effects only and it has no role in the prevention or treatment of visceral KS.
Panretin gel nima vloge pri preprečevanju ali zdravljenju visceralnega KS- a.
Two controlled, multicentre, randomised, double blind parallel group, Phase III studies provided the data for Panretin gel in the treatment of index cutaneous lesions of KS (Table 3).
V dveh kontroliranih, multicentričnih, randomiziranih, dvojno slepih študijah faze III s paralelnimi skupinami, so ugotavljali učinkovitost Panretin gela za zdravljenje indeksiranih kožnih lezij KS- a (razpredelnica 3).
The patient response rate was evaluated using the AIDS Clinical Trials Group (ACTG) criteria for lesion response in KS.
Stopnjo odziva pri bolnikih so analiziraliz merili za odziv lezij pri KS- u Skupine kliničnih študij za AIDS (ACTG).
Best response according to ACTG criteria for vehicle controlled phase
Najboljši odziv po merilih skupine kliničnih študij za AIDS (ACTG) za fazo s kontrolo vehikla
Study 1 (TID, QID)1
Študija 1 (TID, QID) 1
Study 2 (BD)2
Študija 2 (BD) 2
Vehicle Panretin N=134 N=62
Vehikel Panretin N=134 N=62
Clinical Complete Response (CCR)%
Celotni klinični odziv (CCR)%
Partial Response (PR)%
Delni odziv (PR)%
Stable Disease%
Stabilna bolezen%
Progressive Disease%
Progresivna bolezen%
Overall Response%
Skupni odziv%
Protocol-specified dose regimen was application three times a day (TID) escalating to four times a day (QID) after two weeks, with downward adjustments for toxicity 2.
S protokolom določeno odmerjanje je bila uporaba trikrat dnevno (TID), ki se je stopnjevala do štirikrat dnevno (QID) po dveh tednih, s prilagoditvijo navzdol pri toksičnosti 2.
In the open label phase of Study 1 (N = 184), the overall response rate increased to 66.7%.
V odprti fazi študije 1 (N = 184) se je skupna stopnja odziva povečala na 66, 7%.
In Study 2a (N = 99), the overall response rate increased to 56.1%.
V študiji 2a (N = 99) se je skupna stopnja odziva povečala na 56, 1%.
In study 1, of 110 responding patients, 36 (33%) relapsed, while all but four still being on active treatment.
V študiji 1 je od 110 bolnikov, ki so se odzvali, 36 (33%) ponovno zbolelo, medtem ko so z izjemo štirih bili še vsi na aktivnem zdravljenju.
Response rates were analysed both by the patient as the unit of analysis and by the lesion.
V razpredelnici 4 so posredovane posamezne stopnje odziva bolnikov, ki so se zdravili s Panretin gelom v fazi III.
Table 4 provides the individual lesion response rates for patients being treated with Panretin gel in the Phase III studies.
Razpredelnica 4:
Index/ indicator lesion1 responses within patients during the first 12 weeks on study in initial blinded phase
Indeks/ indikator odzivi1 lezij pri bolnikih v času prvih 12 tednov v začetni slepi fazi študije
Patients with given number of index/ indicator lesion responses (CCR or PR) Study 1 Study 2
Študija 2
Number of
Število odzivov
Panretin Vehicle (N=134) Panretin Vehicle (N=72)
Panretin (N=134)
(N=134)
Vehikel (N=134) Panretin (N=62)
(N=62)
Vehikel (N=72)
Lesions2,3
Lezije2, 3
N %4
N% 4 N% 4
At Least One At Least Four
Najmanj ena Najmanj štiri
Study 1, 6 index lesions; Study 2, up to 8 index lesions 2.
Študija 1, 6 indeksnih lezij; študija 2, do 8 indeksnih lezij 2.
In one trial, 29% of the lesions that had reached a partial response (PR) but had not attained clinical complete response (CCR) within the first 12 weeks of treatment developed a CCR during continuing treatment beyond 12 weeks.
V enem poskusu je 29% lezij, ki so dosegle delni odziv (PR), ne pa celotnega kliničnega odziva (CCR) v času prvih 12 tednov zdravljenja, doseglo celotni klinični odziv (CCR) med podaljšanim zdravljenjem po 12 tednih.
It is recommended that Panretin gel should be applied for an initial treatment period of up to 12 weeks.
Priporočamo, da se Panretin gel uporablja za začetno fazo zdravljenja, ki traja do 12 tednov.
If a complete response of a lesion occurs, no further application of Panretin gel should be made to the responding lesion.
Če se doseže celotni odziv lezije, nadaljnja uporaba Panretin gela na taki leziji ni več potrebna.
There are no data regarding the efficacy of Panretin gel when applied to complicated lesions (e. g., when lymphoedema is present).
Ni podatkov oučinkovitosti Panretin gela pri nanosu na komplicirane lezije (npr. v prisotnosti limfedema).